Loncastuximab Tesirine / 5 mg
Product Description
Loncastuximab Tesirine is an innovative monoclonal antibody-drug conjugate (ADC) developed for the treatment of certain aggressive lymphomas. Unlike traditional chemotherapy, it targets a specific protein overexpressed on the surface of cancer cells, allowing for a more precise attack on these cells while minimizing harm to healthy tissues. Clinical studies have demonstrated its effectiveness against diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), offering hope for patients with these challenging diagnoses. The ADC mechanism ensures that the drug is delivered directly to the cancer cells, reducing systemic toxicity and improving quality of life during treatment.
Application
Loncastuximab Tesirine is indicated for the treatment of adult patients with relapsed or refractory DLBCL and MCL who have received at least one prior systemic therapy. It represents a significant advancement in the management of these aggressive forms of lymphoma, providing a new therapeutic option for patients whose disease has progressed despite conventional treatments. The administration of loncastuximab tesirine requires careful consideration of the patient's overall health status and the potential benefits and risks associated with this novel therapy.
Articles:
- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Publication Date: May 11, 2021
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Prof Mehdi Hamadani, Brian Hess, Prof Brad S Kahl, Prof John Radford, Melhem Solh, Anastasios Stathis, Prof Pier Luigi Zinzani, Karin Havenith, Jay Feingold, Shui He, Yajuan Qin, David Ungar, Xiaoyan Zhang, Prof Carmelo Carlo-Stella
https://doi.org/10.1016/S1470-2045(21)00139-X
- Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Publication Date: MAY 13, 2021
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl
https://doi.org/10.1182/blood.2020007512
- A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Publication Date: DECEMBER 02 2019
Brad S. Kahl; Mehdi Hamadani; John Radford; Carmelo Carlo-Stella; Paolo Caimi; Erin Reid; Jay M. Feingold; Kirit M. Ardeshna; Melhem Solh; Leonard T. Heffner; David Ungar; Shui He; Joseph Boni; Karin Havenith; Owen A. O'Connor